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Background: There is little data on the impact of prior criminal activity on the treatment of opioid dependence with
office-based buprenorphine. The goal of this study was to investigate the association between prior criminal charges and
treatment outcomes in a cohort of patients initiating buprenorphine treatment in a primary care practice.
Methods: This was a retrospective study of 252 consecutive patients with opioid dependence who were given at least
one prescription for buprenorphine in a primary care practice. A public database was used to collect data on criminal
charges prior to enrollment. For every month after initiation of treatment, patients who remained in treatment were
classified as “opioid-positive” or “opioid-negative” based on urine drug test results, patient report and clinician assessment.
The primary outcomes of interest were treatment retention at one year and achieving ≥ 6 “opioid negative” months.
Results: Most (80%) of the subjects had at least one prior criminal charge. Those with prior criminal charges
were more likely to have Medicare or Medicaid insurance, to be unemployed, to use cocaine and to have
injected drugs. In the year after initiation of buprenorphine treatment, these subjects had significantly less
opioid-negative months than those without criminal charges (5.1 months vs. 6.4 months; p = 0.030), and were
less likely to have ≥ 6 opioid-negative months (43.2% vs. 58.4%; p = 0.048). While there was no difference in
treatment retention at one-year for those who had any prior history (55.4% vs. 52.0%; p = 0.854), having recent
charges (in the previous two years) was associated with poorer treatment retention and drug outcomes. On the
other hand, having only distant charges (more than two years prior to treatment initiation) was not associated
with poorer outcomes. Using multivariate analysis, recent criminal charges was the only factor significantly
associated with treatment retention at one year and achieving ≥ 6 opioid-negative months.
Conclusions: Subjects with recent criminal charges had poorer treatment retention and opioid-abstinence
outcomes after initiating office-based buprenorphine treatment. These individuals may benefit from more
intensive treatment than is typically offered in a primary care setting.
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Substance dependence is a common medical problem
and is associated with criminal activity (Ball et al., 1983).
While there is wide variability of rates of substance use
disorders in prison populations, the rates are consistently
much higher than the general population (Fazal et al.,
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20132004, 53% of state and 45% of federal prisoners met cri-
teria for drug dependence or abuse, and 13.1% and 9.2%,
respectively, regularly abused opioids, but only 0.3% of
state and 0.4% of federal prisoners were managed with
opioid replacement therapy (Mumola and Karberg 2006).
Given the prevalence of substance use in the criminal
justice population and the current lack of access to
pharmacologic treatment for opioid dependence, as well
as the high rates of recidivism associated with substance
use disorders (Hankansson and Berglund, 2012), there is a
tremendous need for effective treatments. IncarcerationOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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dependence and improve rates of recidivism (Chandler
et al., 2009). For prisoners with opioid dependence, metha-
done maintenance treatment after release from prison
has been associated with a reduction in mortality and
re-incarceration (Dolan et al., 2005, Larney et al. 2011).
Studies suggest that buprenorphine is also a feasible
treatment post-release (Springer et al., 2010), treatment
retention is associated with a reduction in opiate use
and crime (Garcia et al., 2007). and treatment can im-
prove other medical conditions (Springer et al., 2012).
Buprenorphine maintenance therapy may be more accept-
able than methadone to criminal offenders released from
prison (Magura et al., 2009).
While a criminal history may be associated with poorer
treatment retention in methadone maintenance therapy
(Magura et al., 1998, Villafranca et al., 2006, Kelly et al.,
2011, Cox et al., 2012), there is little data on the treatment
outcomes associated with office-based buprenorphine;
one recent study found that a history of incarceration
was not associated with poorer outcomes in office-based
buprenorphine treatment (Wang et al., 2010).
The goal of this study is to evaluate the impact of having
prior criminal charges on treatment outcomes among
patients initiating office-based buprenorphine treatment.
We hypothesized that subjects with prior charges would
not do as well as those without prior criminal charges
and that this association would be strongest for those
with recent charges.Methods
Setting
The Comprehensive Care Practice is a primary care clinic
on the Johns Hopkins Bayview Medical Center campus,
which is staffed by 5 internists, a nurse practitioner, and 3
residents who share a panel of patients. The practitioners
provide general primary care, with a focus of serving
patients with HIV infection and/or substance use disorders.
Visits for opioid dependence occured as routine primary
care visits. There was no uniform protocol or dosing regi-
men, with buprenorphine doses that ranged from 2 to
32 mg, with most patients on 8–16 mg daily. Patients were
typically given a prescription for a one-week supply of
buprenorphine initially and induction occurred at home
or in the office; follow-up occurred weekly to monthly,
based on the provider’s discretion; patients were usually
seen more frequently early in treatment or when there
was continued substance use. Treatment was continued
or discontinued based on the provider’s discretion. The
practice did not provide any additional onsite psychosocial
services and patients were referred to community resources.
A more detailed description of this clinic’s treatment prac-
tices can be found in Soeffing et al., 2009.Subjects
The study included all patients who had been given at
least one prescription for sublingual formulation of
buprenorphine from August 2003 to September 1, 2007.
Data collection
As part of a previously performed study (Soeffing et al.,
2009), a database of all patients who received at least
one prescription for buprenorphine during this period of
time had already been created. Data were collected
retrospectively from the patient medical records. Demo-
graphic information recorded included age, gender, type of
insurance and employment status. Substance abuse history
collected included substances used and history of injection
drug use. Also recorded were relevant comorbidities
(hepatitis C, HIV, chronic pain and chronic psychiatric
illness).
The time period after receiving the first prescription
was divided into twelve monthly blocks for the purposes
of this analysis. Patients were considered to be in treat-
ment for each block in which they were prescribed
buprenorphine at any point. Patients were considered
to be in treatment during the time period covered by
their prescriptions and were considered to be out of
treatment if there was a gap in the period covered by their
prescriptions. For those who dropped out of treatment,
they were considered to be in treatment for the duration
of time covered by their most recent prescription. There
was no fixed protocol for collection of urine drug tests
and patients sometimes did not have urine collected when
they admitted to recent nonprescribed opioid use or when
they had sequential negative urine tests, so for each month
in which the patient was receiving treatment, patients
were classified as “opioid-positive” or “opioid-negative”.
Patients were classified as “opioid-positive” if any of their
urine drug tests during that month were positive for
opioids (other than those prescribed), they reported using
other non-prescribed opioids, or a urine drug test was
not collected and their most recent test was positive
(practitioners would sometimes not collect urine if the
patient reported recent substance use or patients may
have left without leaving a urine specimen). Patients were
classified as “opioid-negative” if all urine drug tests col-
lected during that month were negative for opioids (other
than those prescribed) or if the provider decided not to
test the urine and their most recent test was negative.
We utilized the Maryland Judiciary Case Search website
(http://casesearch.courts.state.md.us/inquiry/inquiry-index.
jsp) to collect data on prior criminal charges. “Criminal
charges” are defined in this study as a written accusation
charging that an individual named has been accused of
committing an act or omitted to do something that is
punishable by law. We did not include traffic offenses.
This database includes data on all criminal charges in
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the defendant name, city and state, date of birth, trial
date, charge, and case disposition. We searched this
database by each patient’s name and birthdate, and
recorded whether the subject had ever had criminal
charges prior to initiating treatment. We tabulated the
total number of cases during their lifetime and in the
two years prior to the date of the first prescription for
buprenorphine. We used “cases” as our unit of measure-
ment rather than “charges” because subjects often had
multiple individual charges associated with each case.
We defined “recent charges” as those within two years
of initiation of treatment and “distant charges” as those
more than two years prior to initiation of treatment.Table 1 Characteristics of subjects with and without prior
criminal charges
Characteristic Any prior No prior p value
criminal charges criminal charges
(N = 202) (N = 50)
Mean Age (SD) 40.2 (9.2) 37.9 (10.8) 0.132
Sex
Male 112 (55.4%) 30 (60.0%) 0.561
Female 90 (44.6%) 20 (40.0%)
Insurance
Commercial 71 (35.1%) 33 (66.0%) <0.001
Medicaid 78 (38.6%) 11 (22.0%) 0.028
Medicare 47 (23.3%) 4 (8.0%) 0.016
None 6 (3.0%) 2 (4.0%) 0.710
Employment Status
Employed 75 (37.1%) 38 (76.0%) <0.001
Unemployed 66 (32.7%) 8 (16.0%) 0.020
Disabled 61 (30.2%) 4 (8.0%) 0.001
Abused Substances
Heroin 176 (87.1%) 33 (66.0%) <0.001
Opioid Rx 47 (23.3%) 25 (50.0%) <0.001
Cocaine 116 (57.4%) 18 (36.0%) 0.007
Alcohol 32 (15.8%) 10 (20.0%) 0.480
Benzodiazepines 18 (8.9%) 5 (10.0%) 0.811Statistical analysis
The data was analyzed to see if having prior criminal
charges was associated with retention and treatment
outcomes. We also divided the cohort with prior charges
into those with “recent charges” (in the two years prior
to the initial visit) and those with only “distant charges”
(more than two years prior to the initial visit), as well as
those with more than or less than the median number
of prior charges. Specific outcomes were retention in
treatment, defined as being in treatment 12 months
after the initial prescription (including those who may
have dropped out temporarily during that year), “opioid-
negative” months, and successful treatment, defined as
achieving ≥6 “opioid-negative” months in a 12-month
period (not necessarily consecutive months).
Bivariate analysis was used to compare demographic
factors and outcomes among subjects with and without
prior criminal charges. Chi-square tests were used to
analyze categorical variables and t tests for continuous
variables. P values less than 0.05 were considered statisti-
cally significant. Multivariate logistic regression was used
to evaluate factors associated with being in treatment at
12 months and achieving ≥6 “opioid-negative” months.
Factors that were associated with these outcomes at a p
value ≤0.1 were included in the multivariate model;
when there was a high collinearity between factors (correl-
ation coefficient >0.4), only one factor was entered into
the model. Analysis was performed using PASW software
(version 18). This study was approved by the Johns
Hopkins Institutional Review Board.IDU 128 (63.4%) 24 (48.0%) 0.047
Co-morbidities
HIV 29 (14.4%) 7 (14.0%) 0.949
HCV 112 (55.4%) 13 (26.0%) <0.001
Psychiatric 103 (51.0%) 22 (44.0%) 0.376
Chronic Pain 35 (17.3%) 11 (22.0%) 0.444
Opioid Rx: prescription opioids, IDU: injection drug use, HIV: human
immunodeficiency syndrome, HCV: hepatitis C antibody positive.Results
The study included 252 patients who had been given
at least one prescription for sublingual formulation of
buprenorphine from August 2003 to September 1, 2007.
Three subjects from the original cohort were not included
because they could not be identified due to gaps in
record-keeping.Prior criminal charges and demographic factors
The number of subjects with criminal charges prior to
initiating treatment was 202 (80.2%). Among the 202
subjects with prior criminal history, the number of prior
cases ranged from 1 to 43 and the median number was
6; 108 (42.9%) subjects had charges in the two years prior
to initiation of treatment. Table 1 provides demographic
and outcome data on subjects with and without prior
criminal charges. A number of characteristics were as-
sociated with having prior criminal charges. Subjects
with prior charges were more likely to be unemployed
or disabled; they were more also more likely to be
uninsured or publicly-insured. Those who reported a
history of heroin and cocaine use were more likely to
have had prior criminal charges, while those who reported
prescription drug abuse were less likely to have had prior
criminal charges. Hepatitis C virus (HCV) infection and
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criminal charges.
Association between criminal charges and
treatment outcomes
The association between prior criminal charges and the
main treatment outcomes is summarized in table 2. Over-
all, subjects with prior criminal charges were as likely to
be in treatment at 12 months as those without (55.4% vs.
52.0%; p = 0.854). However, subjects with criminal charges
were less likely to achieve ≥6 opioid negative months
(43.1% vs. 60.0%; p = 0.032) and had significantly fewer
opioid-negative months than those without prior criminal
charges (mean 5.1 months vs. 6.7 months; p = 0.028).
There appeared to be a dose–response relationship be-
tween number of prior cases and outcomes; subjects with
six or fewer prior cases (at or below the median) did not
have significantly poorer outcomes than those with no
prior history, while those with seven or more prior cases
had significantly fewer opioid-negative months and were
less likely to achieve ≥6 opioid negative months. Both
groups were as likely to remain in treatment as those
with no prior charges.
As shown in Table 2, 108 (42.9%) had criminal charges
within two years of initiating treatment. Recent charges
appeared to have the most significant association with
treatment outcomes. When compared to those who did
not have recent charges (including those with no prior
charges), subjects with charges in the two years prior to
initiation of treatment were significantly less likely to
remain in treatment or to achieve ≥6 opioid negative
months and had significantly fewer opioid-negative months.
On the other hand, those with only distant charges didTable 2 Relationship between prior criminal charges, treatme




Any charges 112 (55.4%)
(n = 202) p = 0.854a
1-6 cases 57 (54.3%)
(n = 105 ) p = 0.973a
≥7 cases 55 (56.7%)
(n = 97) p = 0.755a
Recent charges 58 (53.7)
(n = 108) p = 0.014b
Distant charges 62 (66.0%)
(n = 94) p =0.160a/0.005c
“Recent charges” are those that occurred in the 2 years prior to treatment initiation
ap value for difference with subjects with no prior charges.
bp value for difference with subjects with no recent charges.
cp value for difference with subjects with recent charges.significantly better than those with recent charges and
their outcomes were not significantly different from
those with no prior charges.
Bivariate and multivariate analysis of factors associated
with remaining in treatment at 12 months and achieving
≥6 opioid negative months is shown in Table 3. Subjects
age 40 or less and those with recent charges were less
likely to remain in treatment, while those with prior co-
caine use were more likely. In multivariate analysis, co-
caine use was significantly associated with remaining in
treatment at 12 months, while having recent charges
was associated with a lower likelihood of remaining in
treatment. For the outcome of achieving ≥6 opioid nega-
tive months, subjects with recent charges were less likely
to achieve this outcome, as were those who used heroin.
On multivariate analysis, both heroin use and recent
charges were significantly associated with a lower prob-
ability of achieving ≥6 opioid negative months. Recent
criminal charges was the only factor that was signifi-
cantly associated with both outcomes.
Conclusions
In summary, we found that 80% of patients with opioid
dependence initiating buprenorphine maintenance therapy
in this primary care setting had prior criminal charges.
While a history of criminal charges did not negatively
affect treatment retention, those with prior charges had
significantly fewer opioid-negative months and were less
likely to have ≥6 opioid-negative months. Those with
more prior criminal cases or recent charges did worse
than those with fewer or more distant charges.
Our findings are consistent with a number of studies
conducted with subjects on methadone maintenance.nt retention and drug treatment outcomes




p = 0.028a p = 0.032a
5.36 47 (44.8%)
p = 0.103a p = 0.076a
4.87 40 (41.2%)
p = 0.015a p = 0.031a
4.50 40 (37.0%)
p = 0.004b p = 0.010b
5.84 47 (50.0%)
p = 0.252a/0.031c p = 0.252a/0.063c
, “distant charges” occurred more than 2 years prior to treatment iniation.
Table 3 Bivariate and multivariable analysis of factors associated with being in treatment in 12 months and
achieving ≥6 opioid negative months
Variable In treatment at 12 months ≥6 opioid negative months
OR (CI) AOR (CI) OR (CI) AOR (CI)
Age≤ 40 0.58 (0.36 - 0.97) 0.61 (0.37 – 1.02) 0.96 (0.59 – 1.58)
p = 0.036 p = 0.062 p = 0.960
Female 0.69 (0.42 - 1.14) 1.00 (0.60 – 1.64)
p = 0.148 p = 0.985
Employed 1.04 (0.63 - 1.72) 1.43 (0.87 – 2.36)
p = 0.864 p = 0.160
Heroin abuse 0.97 (0.50 – 1.88) 0.40 (0.20 – 0.79) 0.43 (0.21 – 0.86)
p = 0.924 p = 0.008 p = 0.016
Cocaine abuse 1.80 (1.09 – 2.98) 1.75 (1.05 – 2.92) 1.20 (0.73 – 1.97)
p = 0.022 p = 0.032 p = 0.481
Recent Charges 0.53 (0.32 – 0.88) 0.54 (0.32 – 0.90) 0.51 (0.31 – 0.85) 0.54 (0.32 – 0.91)
(past 2 years) p = 0.015 p = 0.019 p = 0.010 p = 0.021
Statistically significant associations are shown in bold. The following factors were excluded due to high correlation with another factor (indicated in parenthesis):
commercial insurance (employed), prescription opioid abuse (heroin use), injection drug use (heroin use), any prior charges and ≥ 7 prior cases (recent charges).
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having six or more lifetime arrests was associated with
an approximately 3-fold increase in risk of voluntary or
involuntary discharge from a methadone program. Those
awaiting charges, trial or sentence likewise had a higher
risk of voluntary or involuntary discharge. In a previous
analysis, we found that prior charges, particularly recent
charges, were highly correlated with subsequent charges
(Harris et al., 2012); it is possible that some of the poorer
outcomes could have simply been due to incarceration.
Our finding that having any prior criminal charges was
not associated with poorer treatment retention is consist-
ent with a recent study of a cohort of subjects receiving
office-based buprenorphine treatment, which found that a
history of incarceration was not associated with treatment
retention (Wang et al., 2010). However, Wang et al. re-
ported that a history of incarceration was likewise not
associated with increased drug use after initiation of
office-based treatment, while we found poorer treatment
outcomes among those with a history of criminal charges,
particularly those with recent charges. The disparity in
our findings may be due to one or more of the differences
between the two studies. Unlike our study, Wang et al.
excluded individuals who were dependent on other sub-
stances, or if they did not complete the 2-week induction
period, thus perhaps selecting for patients who would tend
to do better in treatment. Additionally, the subjects in
their study received more intensive counseling and moni-
toring than that provided in our primary care setting.
Moreover, many of their subjects who reported never
being incarcerated had a criminal history and they did not
distinguish between recent incarceration and incarceration
in the distant past; our findings suggest that criminalcharges may be a better predictive factor, particularly
when the charges have occurred recently.
Our findings may be relevant to the development of
treatment strategies for recently-incarcerated persons
who are opioid dependent. While we did not look at
incarceration per se, our findings suggest that recent
criminal activity is associated with poorer outcomes. These
individuals may benefit from more intensive treatment
and support than can be offered in a typical primary
care practice. While many may express a preference for
office-based buprenorphine treatment, it is possible
that they would do better in a program (for example, a
traditional methadone maintenance program) that offers
closer supervision and more psychosocial support than is
typically available in a primary care setting. On the other
hand, previous studies suggest that buprenophine main-
tenance is effective for recently incarcerated individuals
(Garcia et al., Magura et al., 2009) and may be preferred
over methadone by incarcerated individuals (Awgu et al.,
2010). It should be noted that in our study, many of those
with recent criminal activity did stay in treatment (over
50% at 12 months) and many were abstinent from opioids.
A major limitation of our study is that we looked only at
criminal charges; not all criminal activity leads to criminal
charges and not all charges are necessarily indicative of
criminal activity (i.e., some may have been wrongly
charged). On the other hand, criminal charges are an
objective measure and likely correlate with criminal
activity. Another limitation is that we looked at the out-
comes of a cohort treated at a single practice in Baltimore;
this may not reflect the outcomes of subjects treated at
other sites or in other localities. We also relied on chart
review and fairly infrequent drug testing for our outcome
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criminal charges recorded in Maryland, and could not
include charges in other states. On the other hand, un-
like many other studies, we used an “intention-to-treat”
model and included everyone who had received at least
one prescription for buprenorphine, not just those who
remained in treatment; so our findings are probably
more representative of the outcomes of all who enter
treatment, not just those who remain in treatment.
Also, we used an objective measure, rather than patient
report.
In summary, our study found that subjects with crim-
inal charges tended to do worse than those with no prior
charges, but the difference appears to be limited to those
with recent criminal charges. Subjects with distant prior
charges (none in the two years before initiation of
treatment) did as well as those with no prior charges.
Although some of the individuals with recent criminal
charges appeared to do well with office-based bupre-
norphine treatment, many may benefit from more inten-
sive treatment and monitoring than can be provided in
a typical primary care setting. Further research is needed
to determine the most effective treatment approach for
these individuals.
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